Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Pot
资讯
2024-03-14
−Pre-SpecifiedInterimAnalysisShowsPositiveSafetyandEfficacyResults;MezagitamabSafeandWellTolerated−TakedaIntendstoInitiateaGlobalPhase3TrialofMezagitamabinPatientswith...